HylTargis™ — Targeted HA-Conjugate Delivery for Solid Tumors
HylTargis™ is an advanced hyaluronan-based conjugate platform engineered for targeted delivery into solid tumors. By exploiting the overexpression of CD44 in tumor microenvironments (TME), HylTargis™ enables selective accumulation, enhanced tissue penetration, and sustained retention of conjugated payloads within tumor masses.
HylTargis™ platform is designed to address the delivery challenges posed by poor water solubility and stability small molecules. Through customized HA conjugation and molecular weight, HylTargis™ enhances the bioavailability and intratumoral distribution of agents that minimizing off-target systemic exposure.
Preclinical validation with CA102N, a HylTargis™ -based conjugate, demonstrated tumor targeting, stromal penetration, sustained retention and tumor growth inhibition in CD44 high expression xenograft animal models. Phase I clinical studies demonstrated strong safety profile in metastatic colorectal cancer (mCRC).
HylTargis™ provides a modular delivery solution for partners aiming to improve efficacy and safety profiles of solid tumor therapeutics — enabling broader applications in pancreatic ductal adenocarcinoma (PDAC), triple-negative breast cancer (TNBC), and other CD44-high malignancies.
